About this trial
Study design: monocentric, retrospective, observational and post-market clinical study.
Purpose: To demonstrate the safety and performance of CoCrMo LOCK bipolar femoral heads. The eligible study population is represented by the entire population that underwent a hip replacement with CoCrMo LOCK bipolar femoral heads from 1st January 2023 onwards at the site in accordance with the indication for use of the product.
Eligibility criteria
Qualifiers
Displaced intracapsular hip fracture (Garden III-IV).
Subjects underwent a Bipolar Hemiarthroplasty with a CoCrMo LOCK Bipolar femoral head as per their Indication For Use from January 1st, 2023, onwards.
No concurrent joint disease at the time of the surgery.
Absence of severe cognitive dysfunction demonstrated by 3 or more correct answers on the Pfeiffer test.
Disqualifiers
Undisplaced or minimally displaced intracapsular hip fracture (Garden I-II).
Any CoCrMo LOCK Bipolar femoral head contraindication for use as reported in the current Instruction For Use.
Pathological fracture secondary to malignant disease.
Subjects with rheumatoid arthritis or symptomatic osteoarthritis.
Trial design
Treatments tested in this trial
- Not listed